CN Patent

CN104016966A — 3-(4-氨基-1,3-二氢-1-氧代-2h-异吲哚-2-基)-2,6-哌啶二酮新晶型及其制备方法

Assigned to Dafeng Acebright Pharmaceuticals Co ltd · Expires 2014-09-03 · 12y expired

What this patent protects

本发明涉及3-（4-氨基-1,3-二氢-1-氧代-2H-异吲哚-2-基）-2,6-哌啶二酮的新晶型及其制备方法，具体地本发明公开了四种新晶型：晶型X、晶型XI、晶型XII和晶型XIII，及其制备方法。本发明的四种新晶型储存稳定且流动性好、静电小，更适合药物制剂，且制备工艺简单高效，可以实现规模化生产，并对环境友好。

USPTO Abstract

本发明涉及3-（4-氨基-1,3-二氢-1-氧代-2H-异吲哚-2-基）-2,6-哌啶二酮的新晶型及其制备方法，具体地本发明公开了四种新晶型：晶型X、晶型XI、晶型XII和晶型XIII，及其制备方法。本发明的四种新晶型储存稳定且流动性好、静电小，更适合药物制剂，且制备工艺简单高效，可以实现规模化生产，并对环境友好。

Drugs covered by this patent

Patent Metadata

Patent number
CN104016966A
Jurisdiction
CN
Classification
—
Expires
2014-09-03
Drug substance claim
No
Drug product claim
No
Assignee
Dafeng Acebright Pharmaceuticals Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.